Rotavirus Prophylaxis Market Report 2026

The rotavirus prophylaxis market size has grown strongly in recent years. It will grow from $9.94 billion in 2025 to $10.87 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to reduction in child mortality through vaccination, increased global immunization coverage, wider availability of oral rotavirus vaccines, growing support from global health organizations, expansion of hospital-based vaccination programs.

The rotavirus prophylaxis market size is expected to see rapid growth in the next few years. It will grow to $16.07 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing focus on universal vaccine coverage, rising investments in pediatric vaccine development, expansion of vaccination programs in emerging economies, growing demand for affordable vaccine formulations, strengthening of immunization infrastructure. Major trends in the forecast period include increasing expansion of national immunization programs, rising adoption of oral rotavirus vaccines, growing focus on pediatric preventive healthcare, enhanced cold-chain distribution management, expansion of public-private vaccination initiatives.

Institutional funding is expected to drive the growth of the rotavirus prophylaxis market in the coming years. Funding from institutions refers to the allocation of resources - such as money, effort, or time - to support a need, program, or project. The rising incidence of rotavirus has attracted funding from both government and private organizations. This financial support provides technical and monetary assistance across various stages of rotavirus vaccine and oral medication development. For example, in April 2025, the American Medical Association, a US-based professional association for physicians, reported that health spending in the U.S. increased by 7.5% in 2023, reaching $4.9 trillion or $14,570 per capita. Therefore, the increasing availability of funding is expected to boost the rotavirus prophylaxis market.

Key companies in the rotavirus prophylaxis market are focusing on technological innovations, such as reassortant hexavalent oral vaccines, to meet the rising demand for broader serotype coverage and enhanced protection against the diverse rotavirus strains prevalent worldwide. Reassortant hexavalent vaccines are developed using advanced viral reassortment technology to target six dominant rotavirus serotypes (G1, G2, G3, G4, G9, and P1A), offering broader protection compared with traditional monovalent or pentavalent vaccines. For instance, in March 2024, Sinovac Biotech Ltd., a China-based biopharmaceutical company, initiated Phase 1 clinical trials for its live, oral reassortant hexavalent rotavirus vaccine to evaluate safety, tolerability, and immunogenicity in adults, children, and infants. The vaccine leverages Vero cell technology and is designed to generate strong immune responses against multiple strains, addressing changing epidemiology and prevalent serotypes with improved effectiveness. Its innovative design supports wider global immunization coverage, particularly in regions with high rotavirus genetic diversity.

In June 2024, the Murdoch Children’s Research Institute (MCRI), an Australia-based child-health research institute, partnered with Incepta Pharmaceuticals to expand access to its RV3-BB rotavirus vaccine in high-burden regions by utilizing Incepta’s manufacturing capacity and market reach. Incepta Pharmaceuticals, based in Bangladesh, is a leading pharmaceutical company engaged in the development, manufacturing, and distribution of a broad range of vaccines and pharmaceutical products.

Major companies operating in the rotavirus prophylaxis market are Merck And Co, GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute Of India Pvt Ltd, Zydus Lifesciences Ltd, Sinovac Biotech Ltd, Hualan Biological Engineering Inc, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd, Shanghai Institute Of Biological Products, Wuhan Institute Of Biological Products, Lanzhou Institute Of Biological Products, Changchun Institute Of Biological Products, Beijing Institute Of Biological Products, Shenzhen Kangtai Biological Products Co Ltd, Minhai Biotechnology Co Ltd, CanSino Biologics Inc, Bharat Serums And Vaccines Limited, Walvax Biotechnology Co Ltd, Clover Biopharmaceuticals Ltd, SK Bioscience Co Ltd.

North America was the largest region in the rotavirus prophylaxis market in 2025. The regions covered in the rotavirus prophylaxis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rotavirus prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the rotavirus prophylaxis market by increasing costs of imported vaccine components, biological raw materials, specialized vials, and cold-chain storage equipment. Vaccine manufacturers and healthcare systems in North America and Europe are most affected due to reliance on cross-border biological supplies, while developing regions face procurement cost pressures. These tariffs are increasing vaccination program costs and impacting pricing negotiations. However, they are also promoting local vaccine manufacturing, regional fill-and-finish facilities, and improved self-sufficiency in vaccine supply chains.

The rotavirus prophylaxis market research report is one of a series of new reports that provides rotavirus prophylaxis market statistics, including rotavirus prophylaxis industry global market size, regional shares, competitors with a rotavirus prophylaxis market share, detailed rotavirus prophylaxis market segments, market trends and opportunities, and any further data you may need to thrive in the rotavirus prophylaxis industry. This rotavirus prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rotavirus prophylaxis involves preventing rotavirus infection through vaccination, protecting infants and young children from a highly contagious disease that causes inflammation of the stomach and intestines. Its main purpose is to safeguard individuals from infections of any severity.

The primary types of rotavirus prophylaxis treatments include Rotarix, Rotavac, Rotavin-M1, oral rehydration solutions, and others. Rotavirus is a virus that leads to severe gastrointestinal illness, including fever, vomiting, and diarrhea. The treatments can be administered via oral, parenteral, and other routes and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and similar channels. The key end users include hospitals, specialty clinics, home care, and others.

The rotavirus prophylaxis market consists of revenues earned by entities by providing services such as vaccination, clinical management, awareness programs and diagnosis. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.